Cargando…

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes

OBJECTIVE. High-grade serous ovarian cancer (HGSOC) is the most common and lethal histological subtype of epithelial ovarian cancer. HGSOC with cyclin E1 gene (CCNE1) amplification and bromodomain and extraterminal 4 (BRD4) amplification have been associated with poor outcomes. Our objective was to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petersen, Shariska, Wilson, Andrew J., Hirst, Jeff, Roby, Katherine F., Fadare, Oluwole, Crispens, Marta A., Beeghly-Fadiel, Alicia, Khabele, Dineo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217738/ https://www.ncbi.nlm.nih.gov/pubmed/32044108 http://dx.doi.org/10.1016/j.ygyno.2020.01.038

Ejemplares similares

Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2015)

Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors
por: Beeghly-Fadiel, Alicia, et al.
Publicado: (2018)

Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis
por: Hufnagel, Demetra H., et al.
Publicado: (2020)

Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records
por: Cozzi, Gabriella D., et al.
Publicado: (2016)

Blood type, ABO genetic variants, and ovarian cancer survival
por: Cozzi, Gabriella D., et al.
Publicado: (2017)

A Case of Extrauterine Endometrial Stromal Sarcoma in the Colon Diagnosed Three Decades after Hysterectomy for Benign Disease
por: Ayuso, Andres, et al.
Publicado: (2013)

CCNE1 amplification among metastatic sites in patients with gynecologic high-grade serous carcinoma
por: Margolis, Benjamin, et al.
Publicado: (2021)

Adrenal Gland Metastasis Is an Unusual Manifestation of Endometrial Cancer
por: Zaidi, Syeda Sadia, et al.
Publicado: (2013)

CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance
por: Sapoznik, Stav, et al.
Publicado: (2017)

Platelets, Thrombocytosis, and Ovarian Cancer Prognosis: Surveying the Landscape of the Literature
por: Hufnagel, Demetra H., et al.
Publicado: (2020)

Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma
por: Chan, Angela MY, et al.
Publicado: (2020)

CCNE1 Amplification and Centrosome Number Abnormality in Serous Tubal Intraepithelial Carcinoma- Further Evidence Supporting its Role as a Precursor of Ovarian High-Grade Serous Carcinoma
por: Kuhn, Elisabetta, et al.
Publicado: (2016)

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
por: Kang, Eun‐Young, et al.
Publicado: (2022)

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
por: Zhao, Zi-Ming, et al.
Publicado: (2019)

Disparities in ovarian cancer survival at the only NCI-designated cancer center in Kansas
por: Petersen, Shariska, et al.
Publicado: (2020)

Incidental placenta increta at the time of prophylactic hysterectomy for Lynch syndrome: Insights into individualized decision-making and surgical timing
por: Nielsen, Tara A., et al.
Publicado: (2015)

Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2021)

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors
por: Rhyasen, Garrett W., et al.
Publicado: (2018)

Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma
por: Drumond-Bock, Ana Luiza, et al.
Publicado: (2023)

CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas
por: NAKAYAMA, KENTARO, et al.
Publicado: (2015)

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
por: Gallo, David, et al.
Publicado: (2022)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis
por: Drumond-Bock, Ana Luiza, et al.
Publicado: (2021)

The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
por: Khabele, Dineo
Publicado: (2014)

Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer
por: Noske, Aurelia, et al.
Publicado: (2016)

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics
por: Noack, Sabrina, et al.
Publicado: (2018)

CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
por: Gorski, Justin W., et al.
Publicado: (2020)

Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis
por: Li, Jie, et al.
Publicado: (2012)

Augmented Serum Amyloid A1/2 Mediated by TNF-induced NF-κB in Human Serous Ovarian Epithelial Tumors
por: Choi, Hyeongjwa, et al.
Publicado: (2017)

Prognostic Values of CCNE1 Amplification and Overexpression in Cancer Patients: A Systematic Review and Meta-analysis
por: Zhao, Haiyue, et al.
Publicado: (2018)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
por: Yao, Shuyang, et al.
Publicado: (2022)

p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry
por: Fadare, Oluwole, et al.
Publicado: (2017)

Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy
por: Gupta, Vijayalaxmi, et al.
Publicado: (2018)

Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival
por: Kotnik, Emilee N., et al.
Publicado: (2023)

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
por: Jewell, Andrea, et al.
Publicado: (2018)

The Impact of the Human Papillomavirus Vaccine on High-Grade Cervical Lesions in Urban and Rural Areas: An Age–Period–Cohort Analysis
por: Shing, Jaimie Z., et al.
Publicado: (2021)

Modeling the Impact of Delaying Bariatric Surgery due to COVID-19: a Decision Analysis
por: Shipe, Maren E., et al.
Publicado: (2020)

Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy
por: Wilson, Andrew J, et al.
Publicado: (2012)

High and intermediate grade ductal carcinoma in-situ of the breast: a comparison of pathologic features in core biopsies and excisions and an evaluation of core biopsy features that may predict a close or positive margin in the excision
por: Fadare, Oluwole, et al.
Publicado: (2009)

Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer
por: Hoover, Alyssa A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ftf4b9on2f2cgvgrgpaqvnma5q